[{"id":"0044ea75-ae77-4594-812e-5bf0e18635e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02499835","created_at":"2021-01-18T12:03:40.058Z","updated_at":"2024-07-02T16:35:41.378Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer","source_id_and_acronym":"NCT02499835","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MVI-816"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 08/09/2021","primary_completion_date":" 08/09/2021","study_txt":" Completion: 07/27/2023","study_completion_date":" 07/27/2023","last_update_posted":"2023-08-01"},{"id":"477d5fbc-6085-4cb2-bdc6-2d42d80ca8fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT01706458","created_at":"2021-01-18T07:26:01.412Z","updated_at":"2024-07-02T16:36:28.940Z","phase":"Phase 2","brief_title":"Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer","source_id_and_acronym":"NCT01706458","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" CSF2 • GZMB","pipe":"","alterations":" ","tags":["CSF2 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Provenge (sipuleucel-T) • MVI-816"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/20/2013","start_date":" 05/20/2013","primary_txt":" Primary completion: 06/12/2017","primary_completion_date":" 06/12/2017","study_txt":" Completion: 08/13/2020","study_completion_date":" 08/13/2020","last_update_posted":"2021-06-18"},{"id":"885f338d-cf33-4d15-971b-5067c41192d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00849121","created_at":"2021-01-18T03:13:56.090Z","updated_at":"2024-07-02T16:36:53.332Z","phase":"Phase 2","brief_title":"Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer","source_id_and_acronym":"NCT00849121","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MVI-816"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 03/16/2009","start_date":" 03/16/2009","primary_txt":" Primary completion: 02/17/2014","primary_completion_date":" 02/17/2014","study_txt":" Completion: 02/17/2014","study_completion_date":" 02/17/2014","last_update_posted":"2019-11-21"},{"id":"5841e871-142e-4c3c-b538-f1f888fad19d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00582140","created_at":"2021-01-18T02:08:27.843Z","updated_at":"2024-07-02T16:36:53.461Z","phase":"Phase 1","brief_title":"Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer","source_id_and_acronym":"NCT00582140","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" CD8 • IFNG • CSF2","pipe":"","alterations":" ","tags":["CD8 • IFNG • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MVI-816"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 03/01/2005","start_date":" 03/01/2005","primary_txt":" Primary completion: 08/01/2008","primary_completion_date":" 08/01/2008","study_txt":" Completion: 08/01/2008","study_completion_date":" 08/01/2008","last_update_posted":"2019-11-19"}]